What does the published research actually say?

The short version

The research record on CJC-1295 is narrow and worth understanding clearly. There is one peer-reviewed Phase 1 pharmacokinetics study in healthy people, published in 2006, covering four dose groups with small sample sizes ^[2]. A separate 2006 study confirmed that the body's natural growth hormone pulse pattern is preserved even while CJC-1295 keeps GH elevated ^[5]. Animal work from 2005 and 2006 identified the compound and showed how it drives GH and IGF-1 responses in rodents ^[1][4].

There is no completed Phase 2 efficacy trial. There is no Phase 3 trial. A Phase 2 study was halted in October 2006 after a participant death, and its primary endpoints were never published ^[8]. The compound is WADA-prohibited at all times and has not been recommended for the FDA 503A compounding bulks list as of 2026 ^[13][16].

The page below goes through each published study, the regulatory timeline, and what the evidence gaps actually mean.

Mechanism: an albumin-tethered GHRH analog

CJC-1295 binds the GHRH receptor (GHRHR), a class-B G-protein-coupled receptor expressed on anterior pituitary somatotrophs — the cells that secrete growth hormone (GH). Receptor activation drives a Gs-protein / adenylyl cyclase / cAMP / PKA cascade that upregulates GH gene transcription and triggers vesicular GH release. Downstream, GH stimulates hepatic IGF-1 production, the principal mediator of GH's anabolic effects ^[1].

The molecule is built on the first 29 residues of human GHRH — the minimum fragment that retains receptor binding — with four protective amino acid substitutions at positions 2, 8, 15, and 27. These substitutions confer resistance to DPP-4 cleavage, deamidation, and oxidation, extending the half-life of the un-modified fragment from roughly seven minutes (native GHRH) to about thirty minutes ^[9]. The DAC modification — a maleimidopropionic acid group at the C-terminus — then covalently bonds the peptide to Cys34 of circulating serum albumin via Michael addition. The albumin tether is the source of the multi-day plasma half-life and is the defining structural difference between "CJC-1295" and the un-tethered backbone, which is commonly mis-marketed as "CJC-1295 without DAC" but is pharmacokinetically a very different molecule ^[1].

A notable subtlety: even under continuous stimulation by CJC-1295, GH secretion remains pulsatile rather than tonically flooded. Ionescu and Frohman (2006) reported that single doses raised trough GH approximately 7.5-fold while preserving the natural pulse architecture — a profile distinct from exogenous recombinant GH, which delivers a steady tonic signal ^[5].

The only Phase 1 paper: Teichman 2006

Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006, remains the only peer-reviewed Phase 1 PK/PD paper on CJC-1295 in healthy adults ^[2].

The trial used a dose-cohort design at 30, 60, 125, and 250 μg/kg administered as a single subcutaneous injection in volunteers aged 21 to 61. Mean plasma GH rose two- to ten-fold above baseline and stayed elevated for at least six days. Mean IGF-1 rose 1.5- to three-fold and stayed elevated for nine to eleven days. In multi-dose cohorts (weekly or biweekly dosing for 28 to 49 days), IGF-1 elevation was sustained out to 28 days ^[2].

Mean plasma half-life across the dose cohorts was 5.8 to 8.1 days ^[3]. This is the central pharmacokinetic property that makes a hypothetical weekly-prescription product even imaginable on paper — separate from the regulatory question of whether such a product exists.

A companion proteomic substudy by Sackmann-Sala et al. (2009) examined serum from eleven healthy young men one week after a single CJC-1295 injection and identified five differentially expressed serum proteins, including a fragment whose abundance correlated linearly with circulating IGF-1 ^[6]. That work is mechanistically useful — it sketches a biomarker fingerprint of GH/IGF-1 axis activation — but it is not a clinical outcomes paper.

What the animal work added

The preclinical record is consistent with the human PK data. Jetté et al. (2005) showed that hGRF(1-29)-albumin bioconjugates activated the GRF receptor on the rat anterior pituitary, producing a roughly four-fold increase in GH area-under-curve over two hours and remaining bioactive in circulation beyond 72 hours after a single subcutaneous bolus ^[1]. This is the paper that named the compound CJC-1295.

Alba et al. (2006) used a GHRH-knockout mouse model — an animal that cannot produce its own GHRH and therefore grows undersized — to test whether CJC-1295 could restore normal growth. Once-daily subcutaneous dosing at 2 μg per injection (roughly 80 μg/kg in a 25 g mouse) for five weeks normalized body length, body weight, and lean body composition; less-frequent dosing at 48- or 72-hour intervals produced only partial restoration. Pituitary somatotroph proliferation and GH mRNA expression also increased ^[4].

The Phase 2 trial that ended in October 2006

ConjuChem registered a Phase 2 trial in HIV-associated visceral adiposity (NCT00267527) that enrolled 192 participants on a weekly subcutaneous dosing schedule ^[8]. The trial was halted in October 2006 after a participant death from an acute coronary event approximately two hours after the eleventh weekly dose.

An independent review judged the death unrelated to study drug and attributed it to pre-existing undiagnosed coronary artery disease. The sponsor halted the program anyway, and primary efficacy endpoint data were never published. The unresolved cardiac signal — even with an external adjudication of "not related" — has been cited in subsequent FDA briefing materials as a contributing concern, most recently in the October 2024 PCAC documents ^[15][17].

No subsequent sponsor has pursued a New Drug Application. There is no Phase 3 trial. The 192-participant Phase 2 study remains the largest controlled human exposure ever conducted, and its primary endpoints sit in the published literature as an open file.

Regulatory timeline, 2023 to 2026

The 503A bulks-list framework is the regulatory lens through which most U.S. compounding-pharmacy access questions get resolved. CJC-1295 has been moving through that framework in measurable steps.

2023. FDA placed CJC-1295 (multiple salt and DAC variants) into interim Category 2 — the "do-not-compound" bucket — pending full PCAC review ^[16].

September 20, 2024. FDA announced removal of CJC-1295 from Category 2 effective September 27, 2024, after the original nominators withdrew their nominations. Removal from Category 2 did not equal placement into Category 1 (eligible). The substance returned to a "no listing" state — not banned by categorization, but still failing all three 503A statutory criteria ^[16].

October 29, 2024. PCAC met to review CJC-1295 for potential bulks-list inclusion. The FDA briefing materials (Docket FDA-2024-N-4777) raised limited human safety data, immunogenicity risk from peptide impurities, theoretical cardiac risk referencing the 2006 fatality, and the absence of a USP monograph. The agency's pre-meeting position was that the compound did not meet 503A bulks-list criteria ^[15].

December 4, 2024. PCAC reconvened on the GH-secretagogue peptide class as a whole (CJC-1295 and ipamorelin among them), consolidated public comment and manufacturer submissions, and reiterated insufficient evidence to support routine 503A compounding access ^[17].

January 7, 2025. FDA released final interim guidance retiring the Category 1/2/3 framework for new nominations. CJC-1295's prior removal from Category 2 stood; the entire scaffold around it was dismantled ^[18].

February 27, 2026. HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience #2461 an intent to reclassify approximately fourteen peptides — explicitly including CJC-1295 — toward a Category 1 framework, with a stated effective date of April 23, 2026 and a planned PCAC review at the July 23-24, 2026 meeting ^[22]. As of May 2026 no Federal Register notice had been issued to operationalize that announcement. The on-the-ground prescribing status remains unchanged.

What's missing from the record

Reading the literature end to end, the gaps are as instructive as the findings.

There is no completed Phase 2 efficacy trial. There is no Phase 3 trial. There is no peer-reviewed randomized controlled trial of the popular CJC-1295 + ipamorelin combination, despite that pairing being the most-discussed protocol in compounding-pharmacy and research-chemical literature ^[12]. The mechanistic rationale for dual GHRH-R / GHS-R1a co-activation is supported by foundational human pharmacodynamic work (Bowers et al. 1990), but that work was conducted with native GHRH and the early ghrelin-receptor agonist GHRP-6 — not with CJC-1295 and ipamorelin specifically ^[12].

Long-term effects of sustained baseline-raised GH and IGF-1 — insulin resistance, edema, joint pain, and the theoretical neoplasia risk inherent to chronic IGF-1 axis activation — are not characterized for CJC-1295. The 5.8-to-8.1-day half-life means a weekly dose produces sustained, supraphysiological exposure rather than the pulsatile pattern the body actually runs on, and the long-term endocrinology of that distinction has not been studied in CJC-1295 specifically ^[3].